NEUROPATHOLOGY CORE

神经病理学核心的总体目标是提供详细的形态、免疫组织化学和 脑血管疾病、血管脑损伤和神经退行性变的生化评估 都是造成认知障碍的原因。这些数据将提供给 计划项目赠款(PPG)，它们将在相关研究中使用。具体目标如下： 1)为患者提供标准化的病理评估和准确的神经病理诊断 随后在PPG中，2)确定缺血性血管病变与脑白质的相对贡献 阿尔茨海默病的改变、阿尔茨海默病的病理改变和路易体对老年人认知损害和痴呆的影响 病人。3)定性和定量地描述动脉粥样硬化， 动脉硬化/动脉硬化和脑淀粉样血管病。将这些异常与 活体测量颈动脉内膜中层增厚和视网膜动脉内径的严重程度。4)至 定义可代表脑损伤的可靠生物标志物的形态参数 完全缺血导致坏死的后果，这种损伤的下游和上游影响 (例如，沃勒变性和跨突触变性)；定义亚梗死的形态相关性 评估皮质内皮质突触的完整性，以及CMS内的细胞群 (星形胶质细胞、小胶质细胞)，可能代表中枢神经系统损伤的足迹。5)评估严重性 阿尔茨海默病在大脑中的变化，提供ABeta和tau病理的定量估计 尸检病人脑实质内的病变。为了区分低聚物和ABeta沉积 新皮质，允许与体内淀粉样蛋白成像和匹兹堡成像的结果进行比较 化合物B(PIB)。6)提供PPG定量神经病理学和PPG内的其他核心和项目 神经血管数据，允许生前神经心理和神经成像之间的相关性 研究和尸检神经病理发现。

The overall goal of the Neuropathology Core is to provide detailed morphologic, immunohistochemical, and biochemical evaluation of cerebrovascular disease, vascular brain injury, and neurodegeneration that may have contributed to cognitive impairment. This data will be provided to other Cores and projects in the program project grant (PPG), where they will be utilized in correlative studies. Specific aims are as follows: 1) To provide standardized pathologic assessment and accurate neuropathologic diagnoses for patients followed in the PPG, 2) To determine the relative contributions of ischemic vascular lesions and white matter alterations, AD pathologic changes, and Lewy bodies, to cognitive impairment and dementia in elderly patients. 3) To characterize, quantitatively and qualitatively, atherosclerosis, arteriosclerosis/arteriolosclerosis, and cerebral amyloid angiopathy. To correlate these abnormalities with severity of cervical carotid intima media thickening and retinal artery diameters measured in vivo. 4) To define morphologic parameters that may represent reliable biomarkers of brain injury which are a consequence of complete ischemia resulting in necrosis, downstream and upstream effects of this injury (e.g. Wallerian and trans-synaptic degeneration); to define morphologic correlates of 'sub-infarctive ischemia;' to assess cortical synaptic integrity within the cortex, as well as cell populations within the CMS (astrocytes, microglia) that may represent footprints of central nervous system injury. 5) To assess severity of Alzheimer disease changes in the brain, providing quantitative estimates of ABeta and tau pathologic lesions within brain parenchyma of autopsy patients. To distinguish oligomeric from ABeta deposition in the neocortex, allowing for comparisons with results from in vivo amyloid imaging with Pittsburgh imaging compound B (PIB). 6) To provide other Cores and Projects within the PPG quantitative neuropathologic and neurovascular data, allowing for correlations between antemortem neuropsychological and neuroimaging studies and autopsy neuropathologic findings.